Market closedNon-fractional
ProPhase Labs/PRPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ProPhase Labs
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Ticker
PRPH
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Garden City, United States
Employees
113
Website
www.prophaselabs.com
ProPhase Labs Metrics
BasicAdvanced
$58M
Market cap
-
P/E ratio
-$0.67
EPS
-0.17
Beta
-
Dividend rate
Price and volume
Market cap
$58M
Beta
-0.17
Financial strength
Current ratio
1.884
Quick ratio
1.52
Long term debt to equity
40.471
Total debt to equity
52.016
Interest coverage (TTM)
-19.55%
Management effectiveness
Return on assets (TTM)
-20.76%
Return on equity (TTM)
-45.03%
Valuation
Price to revenue (TTM)
3.759
Price to book
1.22
Price to tangible book (TTM)
1.96
Price to free cash flow (TTM)
-5.261
Growth
Revenue change (TTM)
-69.59%
Earnings per share change (TTM)
-459.33%
3-year revenue growth (CAGR)
0.97%
3-year earnings per share growth (CAGR)
301.35%
What the Analysts think about ProPhase Labs
Analyst Ratings
Majority rating from 1 analysts.
ProPhase Labs Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.6M
5.88%
Net income
-$6.2M
-28.74%
Profit margin
-172.22%
-32.70%
ProPhase Labs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.20
-$0.30
-$0.51
-$0.07
-
Expected
-$0.14
-$0.20
-$0.26
-$0.28
-$0.25
Surprise
42.86%
53.85%
96.15%
-75.00%
-
ProPhase Labs News
AllArticlesVideos
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress
GlobeNewsWire·2 weeks ago
ProPhase Labs, Inc. (PRPH) Q1 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ProPhase Labs stock?
ProPhase Labs (PRPH) has a market cap of $58M as of July 27, 2024.
What is the P/E ratio for ProPhase Labs stock?
The price to earnings (P/E) ratio for ProPhase Labs (PRPH) stock is 0 as of July 27, 2024.
Does ProPhase Labs stock pay dividends?
No, ProPhase Labs (PRPH) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next ProPhase Labs dividend payment date?
ProPhase Labs (PRPH) stock does not pay dividends to its shareholders.
What is the beta indicator for ProPhase Labs?
ProPhase Labs (PRPH) has a beta rating of -0.17. This means that it has an inverse relation to market volatility.
Buy or sell ProPhase Labs stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.